Navigation Links
Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors
Date:5/28/2009

LINCOLN, R.I., May 28 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. today announced that the Company's product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which there are currently no approved treatments.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090528/NE23594LOGO )

In both studies, there was a statistically significant (p< 0.001 for the high dose group in each study), dose-dependent increase in retinal thickness involving photoreceptor layers as measured by optical coherence tomography (OCT). This statistically-significant effect has also been observed in a recently completed Phase 2 NT-501 study in patients with geographic atrophy associated with dry age-related macular degeneration (AMD), the results of which were reported by Neurotech on March 26, 2009. This effect, which is believed by the Company to be neuroprotective, has also been demonstrated in animals.

NT-501 is an intraocular implant that consists of human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). CNTF, a growth factor capable of rescuing and protecting dying photoreceptors, is delivered directly to the back of the eye in a controlled, continuous basis by means of the Company's proprietary Encapsulated Cell Technology (ECT) platform. Delivery via ECT bypasses the blood-retinal barrier and overcomes a major obstacle in the treatment of retinal disease.

T
'/>"/>

SOURCE Neurotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results
2. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
3. Martek to Announce Second Quarter 2009 Results
4. Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments
5. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
6. Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business
7. Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
8. China Biologic Products Announces Strong First Quarter 2009 Results
9. China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results
10. China Biologic Products Announces 2009 First Quarter Results Conference Call
11. PharmAthene Reports First Quarter 2009 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014 Minerva Neurosciences (NASDAQ: ... therapies to treat neuropsychiatric diseases and disorders, today announced ... vice president of finance and chief accounting officer, effective ... senior executive with more than 20 years of experience ... science companies. His background includes the management of compliance ...
(Date:7/14/2014)... July 14, 2014 PatientCrossroads, ... platform, announced that three PatientCrossroads-based patient registries—DuchenneConnect, ... Phelan-McDermid Syndrome International Registry; and the NephCure ... awarded contracts by the Patient-Centered Outcomes Research ... of a new health data network called ...
(Date:7/13/2014)... University) -- The discovery 30 years ago of soccer-ball-shaped ... of nanotechnology research. Now, there appears to be a ... University, Shanxi University and Tsinghua University in China have ... a hollow molecular cage similar to a carbon buckyball. ... structurepreviously only a matter of speculationdoes indeed exist. , ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 2014 Deep ... is a professional and in-depth study on the current ... China. , The report provides a basic overview of ... Global market analysis and Chinese domestic market analysis are ... competitive landscape of the market. A comparison between the ...
Breaking Biology Technology:Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3
... Number of ... Jobseekers, ... device and diagnostics job board and career fair,company, will host the ... event will take place at the Minneapolis,Airport Marriott from 11 am ...
... The Board of,Directors of Baxter International Inc. (NYSE: ... share of Baxter common stock., This payment represents ... this year by 30 percent. This quarterly dividend is,payable ... of September 10,2008., Baxter International Inc. develops, manufactures ...
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... A. Martell, president and chief,operating officer, will participate ... will provide a corporate overview, including a discussion,of ... picoplatin,the Company,s lead product candidate., * Oppenheimer ...
Cached Biology Technology:DeviceSpace(TM) to Host Medical Device and Diagnostics Career Fair in Minneapolis 2Poniard Pharmaceuticals Announces Upcoming Conference Participation 2
(Date:7/14/2014)... More than 140 years ago, Charles Darwin noticed something ... domestic species are more tame, and they also tend ... floppier ears, patches of white fur, and more juvenile ... for this pattern has proved elusive, but now, in ... , a new hypothesis has been proposed that could ...
(Date:7/14/2014)... of East Anglia have shown how the main psychoactive ... patients. , Research published today reveals the existence ... the drug,s success in shrinking tumours. , It ... synthetic equivalent with anti-cancer properties. , The ... Spain. The team used samples of human breast cancer ...
(Date:7/14/2014)... researchers have developed a technology that could overcome ... fuel a fuel that could replace expensive ... technology is a novel catalyst that performs almost ... reactions, which use electric currents to split water ... is also far more efficient than less-expensive catalysts ...
Breaking Biology News(10 mins):Domestication syndrome: White patches, baby faces and tameness 2UEA research reveals how cannabis compound could slow tumour growth 2Rutgers chemists develop technology to produce clean-burning hydrogen fuel 2
... Academic Affairs John Wiecha, MD, MPH, in the Department ... Health (NIH) American Recovery & Reinvestment Act (ARRA) Challenge ... valued at more than $950,000 will fund a study ... diabetes. The health education will be conducted either ...
... years ago, vertebrates lacked the ability to chew their food. ... a flexible, fused basket of cartilage. This week, an ... the University of Colorado at Boulder published evidence that three ... development of jaws in higher vertebrates. The finding is ...
... adverts, the secret of fertility might not be eternal youth. ... Research at the Consejo Superior de Investigaciones Cientficas in Seville, ... have evolved to protect their seeds. His research is published ... Botany ( http://dx.doi.org/10.1093/aob/mcq160 ). Prof. Herrera said: "No ...
Cached Biology News:Wiecha receives grant to study face-to-face vs. virtual health education for African-American women 2Genetic clues to evolution of jaws in vertebrates unearthed by CU-led team 2
... Fujifilm Life Science LAS-3000mini is a ... to chemiluminescence applications, and the perfect ... Fuiji 's LAS-3000 provides significantly improved ... , Glowell calibration standards validate that ...
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
... ScriptCap™ m7G Capping system ... and all of the components ... 0 on the end of ... These kits feature high efficiency ...
... Fujifilm Life Science FLA-5100 imaging system allows ... large as 40 x 46cm at a ... This system is especially suitable for protein ... array analysis for genomics., Fuji s FLA-5100 ...
Biology Products: